<DOC>
	<DOCNO>NCT02444338</DOCNO>
	<brief_summary>To study safety effectiveness MitraClip System treatment clinically significant functional mitral regurgitation patient New York Heart Association ( NYHA ) Functional Class II Class IV chronic heart failure .</brief_summary>
	<brief_title>A Clinical Evaluation Safety Effectiveness MitraClip System Treatment Clinically Significant Functional Mitral Regurgitation</brief_title>
	<detailed_description>The trial design provide additional evidence regard appropriate recommendation use MitraClip System patient chronic heart failure clinically significant functional mitral regurgitation . Additionally , trial collect evidence regard health economics MitraClip System use patient population .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Key Clinically significant functional mitral regurgitation ( moderatetosevere severe MR ) define European Association Echocardiography , within 90 day prior randomization confirm Echocardiography Core Laboratory Note : The TTE must obtain subject stabilize optimal therapy undergone revascularization and/or CRT , appropriate Assessed investigator optimal standard care therapy heart failure , accord current ESC/HFA guideline dose change heart failure drug ( exception diuretic ) last 2 week immediately prior randomization . Symptomatic document New York Heart Association Class II , III IV heart failure , despite optimal standard care therapy , within 30 day precede randomization Minimum one document hospitalization ( acute care admission emergency room visit ) heart failure within 12 month precede randomization OR value 300 pg/mL BNP 1000 pg/mL NTproBNP optimal medical and/or device management within 90 day precede randomization Note : BNP NTproBNP must obtain subject stabilize optimal therapy undergone revascularization and/or CRT , appropriate Left ventricular ejection fraction ( LVEF ) ≥ 15 % ≤ 35 % ( NYHA Functional Class II ) ≥ 15 % ≤ 45 % ( NYHA Functional Class III IV ) . Note : LVEF need determine one follow method : transthoracic echocardiography ( TTE ) , contrast ventriculography , gate blood pool scan , cardiac magnetic resonance ) within 90 day prior randomization Patient ambulatory able perform 6MWT limit factor ( ) due cardiovascular fitness Key Mitral regurgitation primarily due degenerative disease mitral valve apparatus ( Degenerative MR ) determine transesophageal echocardiography ( TEE ) . Status 1 heart transplant prior orthotropic heart transplantation . Introduction new heart failure drug class within last 2 week prior randomization . Evidence acute coronary syndrome , transient ischemic attack stroke within 90 day prior randomization . Any percutaneous cardiovascular intervention , carotid surgery , cardiovascular surgery , atrial fibrillation ablation within 90 day prior randomization . Therapy without cardioverterdefibrillator ( CRT CRTD ) , Implantable Cardioverter Defibrillator ( ICD ) ) within 90 day prior randomization , revision implant rhythm management device within 90 day prior randomization . Need cardiovascular surgery . Mitral valve surgery consider preferred therapeutic option subject Renal replacement therapy 6Minute Walk Test ( 6MWT ) distance &gt; 475 meter Mitral Valve Area ( MVA ) planimetry &lt; 4.0 cm2 ; MVA planimetry measurable , pressure halftime measurement acceptable ; MVA must confirm Echocardiography Core Laboratory</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>